[go: up one dir, main page]

AR118580A1 - Formulación de tableta vaginal - Google Patents

Formulación de tableta vaginal

Info

Publication number
AR118580A1
AR118580A1 ARP200100936A ARP200100936A AR118580A1 AR 118580 A1 AR118580 A1 AR 118580A1 AR P200100936 A ARP200100936 A AR P200100936A AR P200100936 A ARP200100936 A AR P200100936A AR 118580 A1 AR118580 A1 AR 118580A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
tablet formulation
vaginal tablet
vaginal
glucono
Prior art date
Application number
ARP200100936A
Other languages
English (en)
Inventor
Annette Sfholm
Nils Lindberg
- Strevens Helena Olof
Olov Sterner
Sophie Manner
Ulf Ellervik
Original Assignee
Gedea Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gedea Biotech Ab filed Critical Gedea Biotech Ab
Publication of AR118580A1 publication Critical patent/AR118580A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/366Lactones having six-membered rings, e.g. delta-lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0034Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente se refiere a una composición farmacéutica que comprende glucono d-lactona, que es adecuada para uso en el tratamiento de infecciones microbianas vaginales. Reivindicación 1: Una composición farmacéutica adecuada para administración vaginal, en donde la composición farmacéutica comprende a) de 5 a 30% p/p de Glucono d-lactona (GDL); y b) de 10 a 40% p/p de Hipromelosa (HPMC). Reivindicación 2: La composición farmacéutica de acuerdo con la reivindicación 1, en donde la composición farmacéutica es una tableta.
ARP200100936A 2019-04-05 2020-04-03 Formulación de tableta vaginal AR118580A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19167495 2019-04-05

Publications (1)

Publication Number Publication Date
AR118580A1 true AR118580A1 (es) 2021-10-20

Family

ID=66101895

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200100936A AR118580A1 (es) 2019-04-05 2020-04-03 Formulación de tableta vaginal

Country Status (26)

Country Link
US (1) US12496288B2 (es)
EP (1) EP3976000B1 (es)
JP (1) JP7610847B2 (es)
KR (1) KR102900830B1 (es)
CN (1) CN113660928B (es)
AR (1) AR118580A1 (es)
AU (1) AU2020252268B2 (es)
BR (1) BR112021019999A2 (es)
CA (1) CA3134086A1 (es)
CL (1) CL2021002430A1 (es)
CO (1) CO2021014253A2 (es)
EA (1) EA202192716A1 (es)
ES (1) ES2961736T3 (es)
HU (1) HUE062772T2 (es)
IL (1) IL286942B2 (es)
MA (1) MA56011A (es)
MX (1) MX2021012146A (es)
MY (1) MY208388A (es)
PE (1) PE20220381A1 (es)
PH (1) PH12021552462A1 (es)
PL (1) PL3976000T3 (es)
SG (1) SG11202110236QA (es)
TW (1) TWI846854B (es)
UA (1) UA127823C2 (es)
WO (1) WO2020201515A1 (es)
ZA (1) ZA202106877B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018346361B2 (en) 2017-10-06 2024-07-25 Gedea Biotech Ab Gluconic acid derivatives for use in the treatment and/or prevention of microbial infections
WO2024261110A1 (en) * 2023-06-22 2024-12-26 Gedea Biotech Ab Compositions for promoting growth of lactobacillus crispatus

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR245888A1 (es) * 1989-01-23 1994-03-30 Merrell Pharma Inc Procedimiento para la preparacion de una composicion farmaceutica liquida de derivados de piperidinoalcanol.
FR2710265B1 (fr) * 1993-09-22 1995-10-20 Adir Composition pharmaceutique bioadhésive pour la libération contrôlée de principes actifs.
US6248358B1 (en) * 1998-08-25 2001-06-19 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets and methods of making and using the same
DE69802260T2 (de) * 1998-04-30 2002-07-04 Renata Maria Anna Cavaliere Vesely Pharmazeutische Zusammensetzungen enthaltend Lactobacillus brevis und Lactobacillus salivarius zur Behandlung von Vaginainfektionen
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
US20030017207A1 (en) 2001-05-01 2003-01-23 Lin Shun Y. Compositions and methods for treating vulvovaginitis and vaginosis
BR0215707A (pt) * 2002-04-23 2005-05-03 Lupin Ltd Composição farmacêutica para a liberação controlada de ingredientes ativos e processo para a preparação de uma composição farmacêutica
EP1567131A1 (en) * 2002-11-15 2005-08-31 Ranbaxy Laboratories, Ltd. Bupropion hydrochloride solid dosage forms
EP1872775A1 (en) * 2006-06-29 2008-01-02 Polichem S.A. Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant for the manufacture of a medicament for treating female genital disorders
ITBO20110461A1 (it) * 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
CN109069413B (zh) * 2016-04-06 2022-09-27 盖迪亚生物技术公司 用于治疗阴道真菌感染的葡萄糖酸δ-内酯
AU2018346361B2 (en) 2017-10-06 2024-07-25 Gedea Biotech Ab Gluconic acid derivatives for use in the treatment and/or prevention of microbial infections

Also Published As

Publication number Publication date
IL286942B2 (en) 2025-01-01
KR20210148195A (ko) 2021-12-07
ES2961736T3 (es) 2024-03-13
PH12021552462A1 (en) 2022-06-13
BR112021019999A2 (pt) 2021-12-07
AU2020252268A1 (en) 2021-10-21
IL286942B1 (en) 2024-09-01
HUE062772T2 (hu) 2023-12-28
ZA202106877B (en) 2023-03-29
CN113660928B (zh) 2024-04-05
JP7610847B2 (ja) 2025-01-09
SG11202110236QA (en) 2021-10-28
EA202192716A1 (ru) 2022-01-17
TWI846854B (zh) 2024-07-01
TW202103693A (zh) 2021-02-01
PE20220381A1 (es) 2022-03-18
WO2020201515A1 (en) 2020-10-08
US12496288B2 (en) 2025-12-16
CL2021002430A1 (es) 2022-07-01
CN113660928A (zh) 2021-11-16
MA56011A (fr) 2022-04-06
UA127823C2 (uk) 2024-01-10
EP3976000A1 (en) 2022-04-06
MX2021012146A (es) 2021-12-10
CO2021014253A2 (es) 2021-11-19
JP2022537478A (ja) 2022-08-26
EP3976000B1 (en) 2023-08-02
KR102900830B1 (ko) 2025-12-16
PL3976000T3 (pl) 2023-12-04
EP3976000C0 (en) 2023-08-02
AU2020252268B2 (en) 2025-05-01
IL286942A (en) 2021-12-01
US20220193031A1 (en) 2022-06-23
MY208388A (en) 2025-05-06
CA3134086A1 (en) 2020-10-08

Similar Documents

Publication Publication Date Title
PE20210401A1 (es) Composiciones farmaceuticas que comprenden meloxicam
UY37952A (es) Formulaciones de un inhibidor de la quinasa trk macrocíclica
CL2020002252A1 (es) Formulación oftálmica.
CL2016001411A1 (es) Unidad de dosificación farmacéutica solida de desintegración oral que comprende un componente de estetrol; metodo de preparación; uso para la anticoncepción femenina y en terápia de sustitución hormonal femenina.
CY1109910T1 (el) Χρηση μιας υδροφιλης μητρας η οποια περιεχει ενα παραγωγο πολυακρυλικου οξεος, εναν αιθερα κυτταρινης και εναν παραγοντα αποσαθρωσης για την παραγωγη ενος φαρμακου για την αγωγη ασθενειων των γυναικειων γεννητικων οργανων
MX2019012757A (es) Composicion farmaceutica para administracion oral que comprende enzalutamida.
AR115913A1 (es) Formas de dosificación oral biodisponibles, uso, métodos
AR118580A1 (es) Formulación de tableta vaginal
MX2019015927A (es) Composiciones para administración de fármacos y métodos de uso de las mismas.
CO2023005726A2 (es) Formulación sólida
CY1125075T1 (el) Εκχυλισμα salvia haenkei σαν δραστικος παραγοντας στις διαδικασιες επανεπιθηλιωσης και επουλωσης ιστων
TR201904382T4 (tr) Vajinit tedavisi.
CL2018002705A1 (es) Glucono delta-lactona para el tratamiento de infecciones fúngicas vaginales
MX362717B (es) Formulaciones de agomelatina que comprenden agomelatina en forma de cocristales.
CL2022003426A1 (es) Composición farmacéutica acuosa de levilimab y su uso
BR112021026471A2 (pt) Formulações de dose sólida para a liberação sem agulha
CO2018001531A2 (es) Lisobactina para su uso en el tratamiento de la mastitis bovina
CO2025003585A2 (es) Formulación líquida de belumosudil
PL422140A1 (pl) Zastosowanie totarolu i kompozycja farmaceutyczna zawierająca totarol
NZ742220A (en) Pharmaceutical compositions comprising meloxicam
ZA202311560B (en) Immediate release fixed-dose combination of memantine and donepezil
PE20242349A1 (es) Composicion en espray nasal bioadhesivo, proceso de preparacion y uso
CL2023001196A1 (es) Composición farmacéutica adecuada para administración vaginal en forma de óvulos y uso de la misma.
MX2021000950A (es) Composiciones que comprenden un extracto de arandano americano y fosfolipidos.
UA130743U (uk) Фармацевтична композиція антидіабетичної дії у формі матричних таблеток